Procedure RACHEL in Complex Treatment of Rectal Cancer (RACHEL)

May 2, 2024 updated by: Korotkich Nikolay Nikolaevich, Voronezh N.N. Burdenko State Medical Academy

Complex Treatment of Rectal Cancer

AIM OF RESEARCH. The aim of our research is to improve the results of the combined treatment of patients with locally advanced rectal cancer using endovascular methods and reservoir and plastic surgery.

TASKS OF RESEARCH.

  1. To assess the immediate and long-term results of combined (chemoradiation and surgical) treatment for locally advanced rectal cancer.
  2. To make a comparative evaluation of the results of independent surgical and combined (chemoradiation and surgery) treatment of patients with locally advanced rectal cancer.
  3. To examine functional results of surgical treatment with the formation of "neosphincter" and "neorectum" in patients with colorectal cancer..
  4. To study features of blood supply to the rectum from the pools of the inferior mesenteric and internal iliac arteries, using the method of selective angiography, in connection with the development of endovascular treatment of rectal cancer.
  5. To develop and introduce into clinical practice method of one-stage selective intra-arterial oil chemoembolization of upper, middle and lower rectal arteries in patients with locally advanced rectal cancer, who have a contraindication to preoperative radiotherapy.
  6. To assess the immediate and long-term results of combined (endovascular and surgical) treatment for locally advanced rectal cancer.
  7. To optimize tactics of combined treatment of locally advanced rectal cancer by developing an algorithm of using chemoradiotherapy and endovascular interventions in the preoperative period.

NOVELTY OF RESEARCH.

  1. As a result of research will be designed and implemented a new method of selective intra-arterial chemoembolization in rectal arteries preoperatively in patients with locally advanced rectal cancer.
  2. Substantiated high effectiveness of the proposed technique for the removal of colonic obstruction and, as a consequence perform radical surgical treatment of these patients.
  3. First developed dosage and concentration of chemotherapeutic agent and embolic agent for safe injection when performing selective intra-arterial chemoembolization of rectal arteries.
  4. Developed complex techniques of selective intra-arterial chemoembolization of rectal arteries preoperatively in patients with locally advanced rectal cancer.
  5. Will be made a comparative analysis of the postoperative period and the evaluation of the quality of life of operated patients Obtained data will be presented for use in clinical practice. POSSIBLE APPLICATION AREAS. Results of the research designed for use in the treatment process of departments of Coloproctology, oncology, as well as the educational process of higher and secondary medical institutions.

EXPECTED EFFECTIVENESS.

It is expected that the use of this method of treatment of patients with locally advanced rectal cancer in clinical practice will provide pronounced effect:

  1. Medical and social - improving the quality of care, preservation of social activity of patients, reducing mortality;
  2. Economic - reducing the time of patients' treatment and reducing the number of therapeutic manipulation;
  3. Science and Technology - improving of the training level of medicine workers in the treatment of patients with rectal cancer.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Russian Federation
    • Voronezh Region
      • Voronezh, Voronezh Region, Russian Federation, 394066
        • Voronezh Regional Hospital #1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Clinical diagnosis of rectal cancer T3-4N0-2M0
  • complication of bowel obstruction
  • No allergy on contrast agent
  • Previously not operated about rectal cancer
  • Not older than 75 years

Exclusion Criteria:

  • Older 75 years
  • Previously operated about rectal cancer
  • Allergy to contrast agent
  • No bowel obstruction
  • No rectal cancer
  • No locally advanced rectal cancer
  • Clinical diagnosis of rectal cancer Tis-4N0-2M1 (generalized rectal cancer)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: rectal cancer, surgery
Procedure: usual rectal cancer surgery
Active Comparator: rectal cancer, RACHEL, surgery
Procedure: RACHEL
Other Names:
  • selective endoarterial oil chemoembolisation of upper, middle and lower rectal arteries

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
tumor reduction
Time Frame: 5-10 days
5-10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Voronezh N.N. Burdenko State Medical Academy

Collaborators

Voronesh Regional Clinical Hospital #1

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2006

Primary Completion (Actual)

December 1, 2018

Study Completion (Actual)

December 1, 2018

Study Registration Dates

First Submitted

December 19, 2013

First Submitted That Met QC Criteria

December 27, 2013

First Posted (Estimated)

December 30, 2013

Study Record Updates

Last Update Posted (Actual)

May 6, 2024

Last Update Submitted That Met QC Criteria

May 2, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NNKOR2013

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe